Defense technology has gone from a venture-capital afterthought to the hottest sector in private markets. The numbers make the case on their own: venture funding into defense tech hit a record $14.6 billion in just the first five months of 2026 — surpassing the prior full-year record before June even arrived.
That capital is concentrating in a handful of category leaders. Anduril, now valued at $61 billion, is building autonomous defense systems and winning multibillion-dollar government contracts. Shield AI, at $12.7 billion, is putting AI pilots into military aircraft. Saronic, at $9.25 billion, is doing for autonomous ships what its peers did for drones. (All valuations here are indicative, based on funding rounds — not executable pricing.)
None of the three is publicly traded, and none is likely to be soon. Anduril's founder has floated a listing around fiscal 2028; analysts expect Shield AI to file by mid-2027 at the earliest; Saronic has no announced timeline at all. For investors who want exposure to defense tech stocks pre-IPO, that leaves one practical route: the secondary market, where existing shareholders sell to accredited buyers through regulated venues like AllocationsX.
This guide covers the numbers behind all three companies, the valuation multiples the market is paying (and why those multiples are themselves a risk factor), and the mechanics of pre-IPO investing in the sector.
Why Defense Tech Is the Defining Pre-IPO Story of 2026
Three forces are converging in 2026 to make defense tech the most-watched corner of the private markets.
Record capital formation. The $14.6 billion raised in the sector during the first five months of 2026 didn't just set a pace — it broke the previous full-year record with seven months of the year still to go. When a sector's annual record falls before June, institutional conviction has clearly shifted.
Real revenue, not just narrative. Unlike some venture categories where valuations run ahead of any commercial traction, the leading defense tech companies are posting substantial and fast-growing revenue. Anduril generated roughly $2.2 billion in 2025 revenue, doubling year over year. Shield AI projects revenue above $540 million, growing about 80% annually. Even Saronic, the youngest of the three by scale, is estimated to have produced around $200 million in 2025.
Government contracts as validation. Anduril's $20 billion U.S. Army counter-drone contract, won in March 2026, is the kind of durable, large-scale government commitment that transforms a startup's revenue trajectory — and signals that new-generation defense firms are now winning programs once reserved for legacy primes.
Yet all of this value creation is happening privately. Public-market investors cannot buy a single share of any of these companies. Accredited investors can — through pre-IPO investing on the secondary market.
Anduril: The $61 Billion Anchor of the Sector
If defense tech has a flagship, it's Anduril. In May 2026, the company raised $5 billion in a round led by Thrive Capital and a16z at a $61 billion valuation — roughly double its prior mark. (Indicative, not executable pricing.)
The Fundamentals Behind the Valuation
Anduril's 2025 revenue came in around $2.2 billion, doubled year over year. Then came the contract that changed the conversation: a $20 billion U.S. Army counter-drone award in March 2026. A contract of that size doesn't just add revenue — it provides multi-year visibility that private-market investors typically can only guess at.
The Anduril IPO Question
Founder Palmer Luckey has said he prefers an IPO, targeting around fiscal year 2028. That's a meaningful signal — an eventual listing is the stated plan — but it also means public-market investors may be waiting two more years or longer. For anyone searching "buy Anduril stock" today, the honest answer is that no ticker exists and none is imminent.
How to Buy Anduril Stock Before the IPO
Anduril shares change hands on the secondary market, where employees and early investors sell to verified accredited buyers. Anduril is among the 300+ pre-IPO companies featured on AllocationsX, a regulated Alternative Trading System where accredited investors can browse the opportunity, review reference pricing data, and execute end-to-end on-platform.
Shield AI: AI Pilots at a $12.7 Billion Valuation
Shield AI is the sector's momentum story. In March 2026, the company closed a $1.5 billion Series G at a $12.7 billion valuation — up roughly 140% from its prior $5.3 billion mark. (As always with private rounds: indicative, not executable pricing.)
The revenue picture supports the enthusiasm, if not necessarily the full multiple. Shield AI projects revenue above $540 million, with growth of about 80% year over year. That makes it one of the fastest-scaling companies in the sector — smaller than Anduril in absolute terms, but compounding quickly.
On timing, analysts expect an IPO filing by mid-2027. Until then, Shield AI stock is available only through private secondary transactions. Shield AI is featured on AllocationsX, giving accredited investors a regulated route into a company that most of the market will not be able to touch for at least another year.
Saronic: Autonomous Ships and the Earliest-Stage Bet of the Three
Saronic applies the autonomous-systems playbook to the maritime domain. In March 2026, the company raised $1.75 billion at a $9.25 billion valuation (indicative, not executable pricing), on an estimated $200 million of 2025 revenue.
Saronic is the highest-risk, earliest-stage profile of the trio: the smallest revenue base, the richest valuation relative to that revenue, and no public IPO chatter to anchor a timeline. For investors who want to invest in defense startups at the stage where the outcome distribution is widest — in both directions — Saronic is the purest expression of that trade. It, too, is among the companies featured on AllocationsX.
The Data: Anduril vs. Shield AI vs. Saronic
Metric | Anduril | Shield AI | Saronic |
|---|---|---|---|
Valuation (2026 round) | $61B (May 2026; $5B round led by Thrive Capital and a16z) | $12.7B (March 2026 Series G; $1.5B raised) | $9.25B (March 2026; $1.75B raised) |
Valuation change | Roughly doubled from prior round | Up ~140% from $5.3B | — |
Revenue | ~$2.2B (2025), doubled YoY | >$540M projected, ~80% YoY growth | ~$200M (2025, estimated) |
Implied valuation-to-revenue multiple | ~28x | ~24x (on projected revenue) | ~46x (on estimated revenue) |
Key catalyst | $20B U.S. Army counter-drone contract (March 2026) | Analysts expect IPO filing by mid-2027 | Autonomous ships category leadership |
IPO posture | Palmer Luckey prefers an IPO, targeting ~FY2028 | Filing expected by mid-2027 | No announced timeline |
Valuations are indicative, based on funding rounds, and do not represent executable secondary-market prices. Multiples are simple ratios of round valuations to the revenue figures above.
Valuation Multiples: The Context — and the Risk
The table above deserves a hard look, because the multiples are the most important risk disclosure in this article.
Dividing each company's latest round valuation by its revenue produces ratios of roughly 28x trailing revenue for Anduril, about 24x projected revenue for Shield AI, and approximately 46x estimated revenue for Saronic. These are rich multiples by almost any historical standard, and they price in years of continued hypergrowth.
There are arguments for why the market is paying them. Growth rates are extraordinary — Anduril doubled revenue year over year, and Shield AI is growing about 80% annually. Contract wins like Anduril's $20 billion Army award suggest revenue bases that could expand fast enough to compress those multiples quickly. And record sector funding — $14.6 billion in five months — reflects broad institutional conviction, not one or two exuberant investors.
But investors should treat high multiples as a genuine risk factor, not a footnote:
Compression risk. If growth decelerates, or if public-market comparables de-rate, companies priced at 24x–46x revenue have much further to fall than conservatively valued businesses.
Round prices are not market prices. A valuation set in a competitive funding round reflects one negotiated transaction. It is indicative, not executable pricing, and secondary-market transactions may occur above or below it.
Execution and program risk. Defense revenue depends on government budgets, procurement cycles, and program performance — all of which can shift.
Timeline risk. With likely IPO windows ranging from mid-2027 filings to FY2028 and beyond, capital committed today should be capital you can leave invested for years.
High multiples don't make these companies uninvestable — they make position sizing, entry price, and venue selection matter enormously. Which is exactly where the platform question comes in.
How to Invest in Defense Startups Pre-IPO
Since none of these companies trades publicly, the only way in is to buy pre-IPO shares from existing shareholders on the secondary market. Here's the process on AllocationsX, widely regarded as the best secondaries platform for accredited investors who want both access and executable, regulated transactions:
Create an account at AllocationsX, from your phone or desktop.
Complete accreditation. The platform serves accredited and qualified investors only, with verification required. Current thresholds: $200,000 individual income ($300,000 with a spouse) in each of the past two years, or $1 million-plus net worth excluding your primary residence.
Browse opportunities. Anduril, Shield AI, and Saronic are all featured on the platform, among 300+ pre-IPO companies, with reference pricing data to inform your decisions — particularly valuable in a sector where multiples demand pricing discipline.
Invest securely on-platform. Documents, funding, and execution happen end-to-end through a regulated Alternative Trading System operated by an SEC-registered broker-dealer that is a FINRA and SIPC member.
Track everything in one dashboard — portfolio, pricing, and news.
Exit with liquidity. AllocationsX supports both buying and selling, so a defense tech position acquired in 2026 is not necessarily locked up until an IPO that may be years away.
That two-sided structure is worth underlining for this sector specifically. With Anduril pointing to roughly FY2028 and Shield AI to a mid-2027 filing at the earliest, the ability to sell on the same private stock marketplace where you bought is a meaningful difference from access routes that only work in one direction. Combined with regulated ATS execution, accessible minimums, and mobile-first, end-to-end workflows, it is why many accredited investors consider AllocationsX the best pre-IPO platform for defense tech names.
The SpaceX Precedent
If you want a template for how the defense-adjacent pre-IPO story can end, look at SpaceX. The company completed its IPO on June 12, 2026 at a $1.75 trillion valuation, raising $75 billion — about triple the next-largest IPO in history — and traded past a $2 trillion valuation within its first hour on the Nasdaq. Investors who had bought SpaceX on the secondary market before the listing gained access to a generational company years before public investors could.
That is the thesis for defense tech pre-IPO investing in one sentence: the access window that matters is the one before the ticker exists. It is not a guarantee — most private companies are not SpaceX, and the risks outlined above are real — but it explains why accredited investors are moving into names like Anduril, Shield AI, and Saronic now rather than waiting for 2027 or 2028 listings.
Start Exploring Defense Tech Pre-IPO Opportunities
Anduril, Shield AI, and Saronic are all featured on AllocationsX alongside 300+ other pre-IPO companies. Launch the AllocationsX app to create your account, complete accredited-investor verification, and browse the defense tech opportunities in the platform's regulated secondary market.
Frequently Asked Questions
Can I buy Anduril stock right now?
Not on a public exchange — Anduril is private. Accredited investors can seek exposure through the secondary market, where existing shareholders sell shares through regulated venues. Anduril is among the 300+ companies featured on AllocationsX.
When is the Anduril IPO expected?
Founder Palmer Luckey has said he prefers an IPO, targeting around fiscal year 2028. That is a stated preference, not a filing, so the timeline could shift in either direction.
Is Shield AI stock available to individual investors?
Only through private secondary transactions, and only for accredited investors. Shield AI raised its Series G in March 2026 at a $12.7 billion valuation (indicative, not executable pricing), and analysts expect an IPO filing by mid-2027. Until then, platforms like AllocationsX are the practical access route.
Why are defense tech valuations so high in 2026?
Record sector funding — $14.6 billion in the first five months of 2026 — combined with rapid revenue growth (Anduril doubled to ~$2.2B; Shield AI is growing ~80% annually) and major contract wins like Anduril's $20B Army award. The resulting multiples of roughly 24x–46x revenue are a genuine risk factor: they assume continued hypergrowth and can compress if growth slows.
What is the safest way to invest in defense startups?
No private investment is safe — illiquidity and loss of principal are real risks. But investors can reduce transactional risk by using a regulated venue. AllocationsX operates an Alternative Trading System through an SEC-registered broker-dealer (FINRA and SIPC member), with verified accredited participants, reference pricing data, and end-to-end on-platform execution.
Do I need to be an accredited investor to buy pre-IPO defense stocks?
Yes. AllocationsX is available to accredited and qualified investors only, with verification required. The current thresholds are $200,000 in individual income ($300,000 with a spouse) in each of the past two years, or $1 million-plus in net worth excluding your primary residence. The INVEST Act, which passed the House 302–123 in December 2025 and awaits Senate action, would add a free FINRA-administered exam as an alternative qualification path.
AllocationsX is operated by Allocations Securities, LLC, an SEC-registered broker-dealer and member of FINRA and SIPC, operating an Alternative Trading System under Regulation ATS. Available to accredited and qualified investors only; verification required. Private investments involve significant risk, including illiquidity and possible loss of principal. Valuations referenced are indicative, based on secondary-market activity or last funding rounds, and may not reflect executable prices. Nothing in this article constitutes tax, legal, investment, or accounting advice.
